Investigational afatinib used in non-small cell lung cancer treatment helped patients live longer compared with pemetrexed/cisplatin, according to the results of a new phase 3 clinical trial.
Investigational afatinib used in non-small cell lung cancer (NSCLC) treatment helped patients live longer compared with pemetrexed/cisplatin, according to the results of a new phase 3 clinical trial.
Boehringer Ingelheim Pharmaceuticals presented the results of the LUX-Lung 3 trial at the American Society of Clinical Oncology 2012 Meeting in early June.
The study evaluated 345 patients with stage IIIb or IV NSCLC who harbored a variety of epidermal growth factor receptor (EGFR) mutations. Patients assigned to the afatinib arm lived for 11.1 months before tumor progression, versus 6.9 months for those patients in the chemotherapy arm.
“Data from LUX-Lung 3 show that…afatinib demonstrated a significant and clinically meaningful delay in the progression of NSCLC, compared with combination pemetrexed and cisplatin,” said Berthold Greifenberg, MD, vice president of clinical development and medical affairs – oncology for Boehringer Ingelheim.
EGFR mutation-positive lung cancer is more common than researchers previously believed, according to Lecia V. Sequist, MD, MPH, one of the principal investigators for LUX-Lung 3 and a medical oncologist at Massachusetts General Hospital Cancer Center. “There may be up to 38,000 Americans diagnosed with this disease each year. There is still a great need for additional treatment options, especially in the United States, where there are currently no therapies approved specifically for use in EGFR mutation-positive lung cancer,” Dr Sequist said.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.